Muscarinic antagonists

Last updated: September 12, 2024

Muscarinic antagonists

Watch later

Watch later

Anxiety disorders: Clinical
Blood products and transfusion: Clinical
Blood groups and transfusions
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Diabetes mellitus: Clinical
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Valvular heart disease: Clinical
Chest trauma: Clinical
Shock: Clinical
Peripheral vascular disease: Clinical
Leg ulcers: Clinical
Aortic aneurysms and dissections: Clinical
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Sympathomimetics: Direct agonists
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Loop diuretics
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Positive inotropic medications
Antiplatelet medications
Blistering skin disorders: Clinical
Bites and stings: Clinical
Burns: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Adrenal insufficiency: Clinical
Neck trauma: Clinical
Insulins
Mineralocorticoids and mineralocorticoid antagonists
Glucocorticoids
Abdominal pain: Clinical
Appendicitis: Clinical
Gastrointestinal bleeding: Clinical
Peptic ulcers and stomach cancer: Clinical
Inflammatory bowel disease: Clinical
Diverticular disease: Clinical
Gallbladder disorders: Clinical
Pancreatitis: Clinical
Cirrhosis: Clinical
Hernias: Clinical
Bowel obstruction: Clinical
Abdominal trauma: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Venous thromboembolism: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Thrombolytics
Fever of unknown origin: Clinical
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Skin and soft tissue infections: Clinical
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Acute kidney injury: Clinical
Kidney stones: Clinical
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Traumatic brain injury: Clinical
Lower back pain: Clinical
Spinal cord disorders: Pathology review
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Osmotic diuretics
Opioid antagonists
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Pulmonary corticosteroids and mast cell inhibitors
Joint pain: Clinical
Anatomy clinical correlates: Clavicle and shoulder
Anatomy clinical correlates: Axilla
Anatomy clinical correlates: Arm, elbow and forearm
Anatomy clinical correlates: Wrist and hand
Anatomy clinical correlates: Median, ulnar and radial nerves
Anatomy clinical correlates: Bones, joints and muscles of the back
Anatomy clinical correlates: Hip, gluteal region and thigh
Anatomy clinical correlates: Knee
Anatomy clinical correlates: Leg and ankle
Anatomy clinical correlates: Foot
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Antigout medications

Transcript

Watch video only

Muscarinic antagonists, or antimuscarinic medications, are a class of medications that prevent muscarinic receptors of the parasympathetic nervous system from getting stimulated by acetylcholine.

Okay, first things first, the nervous system is divided into the central nervous system, so the brain and spinal cord; and the peripheral nervous system.

The peripheral nervous system can be divided into the somatic nervous system, which controls voluntary movement of our skeletal muscles; and the autonomic nervous system, which is further divided into the sympathetic and parasympathetic nervous systems, and controls the involuntary movement of the smooth muscles, and the glands of our organs.

Now, the autonomic nervous system is made up of a relay that includes two neurons.

We’ll focus on just the parasympathetic nervous system.

Signals for the parasympathetic nervous system start in the hypothalamus.

These hypothalamic neurons synapse with nuclei in the brainstem or spinal cord, which send out signals to preganglionic neurons that travel to the rest of the body.

Their targets are the parasympathetic ganglion, which consist of many postganglionic neuron cell bodies and are located nearby or directly in the target organs.

The postganglionic neurons extend the rest of the way to the target cell, where they release the neurotransmitter acetylcholine, which is why they are also called cholinergic neurons.

Acetylcholine binds to a type of receptor, known as muscarinic receptors, on the cells of target organs, which allow the parasympathetic nervous system to trigger a ‘rest and digest’ response, meaning that it keeps body-energy use as low as possible to stimulate activities like digestion.

It acts in the heart, slowing the heart rate and reducing the cardiac output.

In the gastrointestinal tract, it increases its motility to stimulate digestion and defecation.

In the bladder, it causes constriction of the bladder muscle, called the detrusor muscle, which stimulates urination.

In salivary, sweat, and lacrimal glands, it increases their secretions.

In the liver, it triggers glucose storage to reduce blood glucose levels.

In the lungs, it causes bronchoconstriction, since in a relaxed state our cells do not consume as much oxygen.

In the eyes, it triggers miosis, or constriction of the pupils, to improve close vision and stimulates the contraction of the ciliary muscles, increasing the outflow of aqueous humor, which is the fluid in the anterior chamber of the eye, and this decreases the intraocular pressure.

Finally, its effects on the brain are extremely complicated, but generally, they cause overall stimulation, and they participate in many wanted and unwanted functions, such as movement control and vomiting, respectively.

Alright, so medications that block the effects of acetylcholine on muscarinic receptors are called muscarinic antagonists or antimuscarinic medications.

Now, the most famous muscarinic antagonist is atropine.

Atropine blocks the “rest and digest” effect from the parasympathetic system, so clinically, it can be used to treat bradycardia, or slowed heart rate.

It decreases bladder smooth muscle contraction so it’s useful for preventing nocturnal enuresis, or bedwetting, in children.

Ophthalmologists can also use atropine to dilate the pupils.

Finally, it’s an antidote for poisoning by anticholinesterases like organophosphates found in pesticides. These agents prolong the effect of acetylcholine by inhibiting their break down, so atropine can help by simply blocking the muscarinic receptors.

Now, for side effects, atropine can produce: tachycardia, or increased heart rate; constipation and urinary retention; dry mouth, skin and eyes; and blurry vision.

The more severe side effects include hyperthermia, dizziness, confusion, and delirium.

It’s also contraindicated in individuals suffering from narrow angle glaucoma since it can worsen the obstruction of aqueous humor drainage.

Key Takeaways

Muscarinic antagonists, also known as antimuscarinic medications, are a class of drugs that block the activation of muscarinic receptors of the parasympathetic nervous system. Examples of muscarinic antagonists include atropine, scopolamine, and ipratropium. These drugs are used to treat a variety of conditions, such as asthma, glaucoma, and urinary incontinence. They can also be used to treat the symptoms of poisoning from organophosphate insecticides.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Muscarinic receptor subtypes in airways" Life Sci (1993)
  5. "Pharmacologic therapy of obstructive airway disease" Clin Chest Med (1990)
  6. "[Atropine. Principles and rules of utilization]" Rev Prat (2001)
  7. "Antimuscarinic drugs" Prof Nurse (2004)